Metabolic-Associated Fatty Liver Disease
Conditions
Interventions
Test group:Patients will receive digital therapy
Sponsors
Department of Infectious Disease, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China(The People's Hospital of Nanhai, Foshan)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) MAFLD diagnosis aligned with the latest international expert consensus, defined as hepatic steatosis confirmed by abdominal ultrasound, combined with overweight/obesity, type 2 diabetes, or metabolic syndrome. (2) Age 18–65 years. (3) Body mass index (BMI) =24 kg/m². (4) Proficiency in smartphone use. (5) Willingness to participate, adhere to follow-up protocols, and provide signed informed consent.
Exclusion criteria
Exclusion criteria: (1) History of viral hepatitis, cirrhosis, or hepatocellular carcinoma. (2) Pregnancy or lactation. (3) Major cardiovascular or cerebrovascular diseases, severe renal/hepatic dysfunction, or malignancies. (4) Severe respiratory, cardiac, or neurological conditions incompatible with dietary/exercise interventions or requiring alternative therapies. (5) Diagnosed psychiatric disorders (e.g., anxiety, depression). (6) Other factors deemed unsuitable by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| body mass index, BMI;Controlled Attenuation Parameter (CAP) and Liver Stiffness Measurement (LSM) by FibroTouch;ALT;GGT;TG;Waist-to-hip ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvements in Lifestyle and Health Behaviors; | — |
Countries
China
Contacts
Public ContactYongchun Li
Department of Infectious Disease, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China(The People's Hospital of Nanhai, Foshan)
Outcome results
None listed